Skip to main content
Erschienen in: Clinical and Experimental Nephrology 10/2020

19.06.2020 | Original article

Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)

verfasst von: Hitoshi Yokoyama, Ryohei Yamamoto, Enyu Imai, Shoichi Maruyama, Hitoshi Sugiyama, Kosaku Nitta, Tatsuo Tsukamoto, Shunya Uchida, Asami Takeda, Toshinobu Sato, Takashi Wada, Hiroki Hayashi, Yasuhiro Akai, Megumu Fukunaga, Kazuhiko Tsuruya, Kosuke Masutani, Tsuneo Konta, Tatsuya Shoji, Takeyuki Hiramatsu, Shunsuke Goto, Hirofumi Tamai, Saori Nishio, Arimasa Shirasaki, Kojiro Nagai, Kunihiro Yamagata, Hajime Hasegawa, Hidemo Yasuda, Shizunori Ichida, Tomohiko Naruse, Kei Fukami, Tomoya Nishino, Hiroshi Sobajima, Satoshi Tanaka, Toshiyuki Akahori, Takafumi Ito, Yoshio Terada, Ritsuko Katafuchi, Shouichi Fujimoto, Hirokazu Okada, Eiji Ishimura, Junichiro James Kazama, Keiju Hiromura, Tetsushi Mimura, Satashi Suzuki, Yosuke Saka, Tadashi Sofue, Yusuke Suzuki, Yugo Shibagaki, Kiyoki Kitagawa, Kunio Morozumi, Yoshiro Fujita, Makoto Mizutani, Takashi Shigematsu, Kengo Furuichi, Keiji Fujimoto, Naoki Kashihara, Hiroshi Sato, Seiichi Matsuo, Ichiei Narita, Yoshitaka Isaka

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of the present study was to clarify the prevalence of immunosuppressive drug use and outcomes in elderly and non-elderly patients with primary membranous nephropathy (MN) in nationwide real-world practice in Japan.

Patients and methods

Between 2009 and 2010, 374 patients with primary nephrotic syndrome were enrolled in the cohort study (The Japan Nephrotic Syndrome Cohort Study, JNSCS), including 126 adult patients with MN. Their clinical characteristics were compared with those of nephrotic patients with primary MN registered in a large nationwide registry (The Japan Renal Biopsy Registry, J-RBR). Outcomes and predictors in the elderly (≥ 65 years) and non-elderly groups were identified.

Results

Similar clinical characteristics were observed in JNSCS patients and J-RBR patients (n = 1808). At the early stage of 1 month, 84.1% of patients were treated with immunosuppressive therapies. No significant differences were observed in therapies between age groups. However, elderly patients achieved complete remission (CR) more frequently than non-elderly patients, particularly those treated with therapies that included corticosteroids. No significant differences were noted in serum creatinine (sCr) elevations at 50 or 100%, end-stage kidney disease, or all-cause mortality between age groups. Corticosteroids were identified as an independent predictor of CR (HR 2.749, 95%CI 1.593–4.745, p = 0.000) in the multivariate Cox’s model. sCr levels, hemoglobin levels, immunosuppressants, clinical remission, and relapse after CR were independent predictors of sCr × 1.5 or × 2.0.

Conclusion

Early immunosuppressive therapy including corticosteroids for primary MN showed better remission rates in elderly patients in a nationwide cohort study.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Hull RP, Goldsmith DJA. Nephrotic syndrome in adults. BMJ. 2008;336:1185–9.CrossRef Hull RP, Goldsmith DJA. Nephrotic syndrome in adults. BMJ. 2008;336:1185–9.CrossRef
3.
Zurück zum Zitat Shiiki H, Saito T, Nishitani Y, Mitarai T, Yorioka N, Yoshimura A, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400–7.CrossRef Shiiki H, Saito T, Nishitani Y, Mitarai T, Yorioka N, Yoshimura A, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400–7.CrossRef
4.
Zurück zum Zitat Deegens JK, Wetzels JF. Membranous nephropathy in the older adult: epidemiology, diagnosis and management. Drugs Aging. 2007;24:717–32.CrossRef Deegens JK, Wetzels JF. Membranous nephropathy in the older adult: epidemiology, diagnosis and management. Drugs Aging. 2007;24:717–32.CrossRef
5.
Zurück zum Zitat Christiansen CF, Schmidt M, Lamberg AL, Horvath-Puho E, Baron JA, Jespersen B, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014;12:1449–544.CrossRef Christiansen CF, Schmidt M, Lamberg AL, Horvath-Puho E, Baron JA, Jespersen B, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014;12:1449–544.CrossRef
7.
Zurück zum Zitat Wu HM, Tang JL, Cao L, Sha ZH, Li Y. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev. 2012;4:CD003964. Wu HM, Tang JL, Cao L, Sha ZH, Li Y. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev. 2012;4:CD003964.
8.
Zurück zum Zitat Soeiro EMD, Koch VH, Fujimura MD, Okay Y. Influence of nephrotic state on the infectious profile in childhood idiopathic nephrotic syndrome. Rev Hosp Clin Fac Med Sao Paulo. 2004;59:273–8.CrossRef Soeiro EMD, Koch VH, Fujimura MD, Okay Y. Influence of nephrotic state on the infectious profile in childhood idiopathic nephrotic syndrome. Rev Hosp Clin Fac Med Sao Paulo. 2004;59:273–8.CrossRef
9.
Zurück zum Zitat Christiansen CF, Onega T, Svarke C, Kormendine Farkas D, Jespersen B, Baron JA, et al. Risk and prognosis of cancer in patients with nephrotic syndrome. Am J Med. 2014;127:871–7.CrossRef Christiansen CF, Onega T, Svarke C, Kormendine Farkas D, Jespersen B, Baron JA, et al. Risk and prognosis of cancer in patients with nephrotic syndrome. Am J Med. 2014;127:871–7.CrossRef
10.
Zurück zum Zitat Ordonez JD, Hiatt R, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44:638–42.CrossRef Ordonez JD, Hiatt R, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44:638–42.CrossRef
11.
Zurück zum Zitat Komatsuda A, Nakamoto Y, Imai H, Yasuda T, Yanagisawa MM, Wakui H, et al. Kidney diseases among the elderly. A clinicopathological analysis of 247 elderly patients. Intern Med. 1993;32:377–81.CrossRef Komatsuda A, Nakamoto Y, Imai H, Yasuda T, Yanagisawa MM, Wakui H, et al. Kidney diseases among the elderly. A clinicopathological analysis of 247 elderly patients. Intern Med. 1993;32:377–81.CrossRef
12.
Zurück zum Zitat Yokoyama H, Taguchi T, Sugiyama H, Sato H. Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:557–63.CrossRef Yokoyama H, Taguchi T, Sugiyama H, Sato H. Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:557–63.CrossRef
13.
Zurück zum Zitat Yokoyama H, Sugiyama H, Sato H, Taguchi T, Nagata M, Matsuo S, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:903–20.CrossRef Yokoyama H, Sugiyama H, Sato H, Taguchi T, Nagata M, Matsuo S, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:903–20.CrossRef
14.
Zurück zum Zitat Kidney Disease Improving Global Outcomes. KDIGO Clinical practice guideline for glomerulonephritis, Chap. 7: idiopathic membranous nephropathy. Kidney Int Suppl. 2012;2:186–97.CrossRef Kidney Disease Improving Global Outcomes. KDIGO Clinical practice guideline for glomerulonephritis, Chap. 7: idiopathic membranous nephropathy. Kidney Int Suppl. 2012;2:186–97.CrossRef
15.
Zurück zum Zitat Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20:342–70.CrossRef Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016;20:342–70.CrossRef
16.
Zurück zum Zitat Barbour S, Beaulieu M, Gill J, Espino-Hernandez G, Reich HN, Levin A. The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. Clin Kidney J. 2014;7:538–45.CrossRef Barbour S, Beaulieu M, Gill J, Espino-Hernandez G, Reich HN, Levin A. The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. Clin Kidney J. 2014;7:538–45.CrossRef
17.
Zurück zum Zitat Yokoyama H, Sugiyama H, Narita I, Saito T, Yamagata K, Nishio S, et al. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2015;19:496–505.CrossRef Yokoyama H, Sugiyama H, Narita I, Saito T, Yamagata K, Nishio S, et al. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2015;19:496–505.CrossRef
18.
Zurück zum Zitat Yamamoto R, Imai E, Maruyama E, Yokoyama H, Sugiyama H, Nitta K, et al. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol. 2019;22:1266–80.CrossRef Yamamoto R, Imai E, Maruyama E, Yokoyama H, Sugiyama H, Nitta K, et al. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol. 2019;22:1266–80.CrossRef
19.
Zurück zum Zitat Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, et al. Committee for Standardization of Renal Pathological Diagnosis and Working Group for Renal Biopsy Database, Japanese Society of Nephrology, Tokyo, Japan: Japan Renal Biopsy Registry: Japan Renal Biopsy Registry: the first nationwide, web based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011;15:493–503.CrossRef Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, et al. Committee for Standardization of Renal Pathological Diagnosis and Working Group for Renal Biopsy Database, Japanese Society of Nephrology, Tokyo, Japan: Japan Renal Biopsy Registry: Japan Renal Biopsy Registry: the first nationwide, web based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011;15:493–503.CrossRef
20.
Zurück zum Zitat Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
21.
Zurück zum Zitat Matsuo S, Imai E, Saito T, Taguchi T, Yokoyama H, Narita I, et al. Guidelines for the treatment of nephrotic syndrome. Nihon Jinzo Gakkai Shi. 2011;53:78–123 [in Japanese]. Matsuo S, Imai E, Saito T, Taguchi T, Yokoyama H, Narita I, et al. Guidelines for the treatment of nephrotic syndrome. Nihon Jinzo Gakkai Shi. 2011;53:78–123 [in Japanese].
22.
Zurück zum Zitat Yoshimoto K, Yokoyama H, Wada T, Furuichi K, Sakai N, Iwata Y, et al. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int. 2004;65:148–53.CrossRef Yoshimoto K, Yokoyama H, Wada T, Furuichi K, Sakai N, Iwata Y, et al. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int. 2004;65:148–53.CrossRef
23.
Zurück zum Zitat Yamaguchi M, Ando M, Katsuno T, Tsuboi N, Maruyama S. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan. Ren Fail. 2018;40:435–41.CrossRef Yamaguchi M, Ando M, Katsuno T, Tsuboi N, Maruyama S. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan. Ren Fail. 2018;40:435–41.CrossRef
24.
Zurück zum Zitat Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant. 2009;24:3082–8.CrossRef Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant. 2009;24:3082–8.CrossRef
25.
Zurück zum Zitat Yamaguchi M, Ando M, Yamamoto R, Akiyama S, Kato S, Katsuno T, et al. Patient age and the prognosis of idiopathic membranous nephropathy. PLoS ONE. 2014;9:e110376.CrossRef Yamaguchi M, Ando M, Yamamoto R, Akiyama S, Kato S, Katsuno T, et al. Patient age and the prognosis of idiopathic membranous nephropathy. PLoS ONE. 2014;9:e110376.CrossRef
26.
Zurück zum Zitat Bae E, Lee SW, Park S, Kim DK, Lee H, Huh H, et al. Treatment and clinical outcomes of elderly idiopathic membranous nephropathy: a multicenter cohort study in Korea. Arch Gerontol Geriatr. 2018;76:175–81.CrossRef Bae E, Lee SW, Park S, Kim DK, Lee H, Huh H, et al. Treatment and clinical outcomes of elderly idiopathic membranous nephropathy: a multicenter cohort study in Korea. Arch Gerontol Geriatr. 2018;76:175–81.CrossRef
27.
Zurück zum Zitat Xu J, Hu X, Xie J, Chen N. Management of membranous nephropathy in Asia. Kidney Dis (Basel). 2015;1:119–25.CrossRef Xu J, Hu X, Xie J, Chen N. Management of membranous nephropathy in Asia. Kidney Dis (Basel). 2015;1:119–25.CrossRef
28.
Zurück zum Zitat Hayashi N, Akiyama S, Okuyama H, Matsui Y, Adachi H, Yamaya H, et al. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2015;19:797–803.CrossRef Hayashi N, Akiyama S, Okuyama H, Matsui Y, Adachi H, Yamaya H, et al. Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2015;19:797–803.CrossRef
29.
Zurück zum Zitat Hayashi N, Okada K, Matsui Y, Fujimoto K, Adachi H, Yamaya H, et al. Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy. Nephrol Dial Transplant. 2018;33:832–40.CrossRef Hayashi N, Okada K, Matsui Y, Fujimoto K, Adachi H, Yamaya H, et al. Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy. Nephrol Dial Transplant. 2018;33:832–40.CrossRef
30.
Zurück zum Zitat Hara S, Tsuji T, Fukasawa Y, Hisano S, Morito S, Hyodo T, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474:735–43.CrossRef Hara S, Tsuji T, Fukasawa Y, Hisano S, Morito S, Hyodo T, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474:735–43.CrossRef
31.
Zurück zum Zitat Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36–46.CrossRef Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36–46.CrossRef
34.
Zurück zum Zitat Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 2002;61:1635–45.CrossRef Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 2002;61:1635–45.CrossRef
35.
Zurück zum Zitat Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013;9:443–58.CrossRef Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013;9:443–58.CrossRef
36.
Zurück zum Zitat Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;2013(Suppl. 3):1–150. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;2013(Suppl. 3):1–150.
37.
Zurück zum Zitat Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant. 2017;32(suppl-1):i57–i64.CrossRef Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant. 2017;32(suppl-1):i57–i64.CrossRef
Metadaten
Titel
Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)
verfasst von
Hitoshi Yokoyama
Ryohei Yamamoto
Enyu Imai
Shoichi Maruyama
Hitoshi Sugiyama
Kosaku Nitta
Tatsuo Tsukamoto
Shunya Uchida
Asami Takeda
Toshinobu Sato
Takashi Wada
Hiroki Hayashi
Yasuhiro Akai
Megumu Fukunaga
Kazuhiko Tsuruya
Kosuke Masutani
Tsuneo Konta
Tatsuya Shoji
Takeyuki Hiramatsu
Shunsuke Goto
Hirofumi Tamai
Saori Nishio
Arimasa Shirasaki
Kojiro Nagai
Kunihiro Yamagata
Hajime Hasegawa
Hidemo Yasuda
Shizunori Ichida
Tomohiko Naruse
Kei Fukami
Tomoya Nishino
Hiroshi Sobajima
Satoshi Tanaka
Toshiyuki Akahori
Takafumi Ito
Yoshio Terada
Ritsuko Katafuchi
Shouichi Fujimoto
Hirokazu Okada
Eiji Ishimura
Junichiro James Kazama
Keiju Hiromura
Tetsushi Mimura
Satashi Suzuki
Yosuke Saka
Tadashi Sofue
Yusuke Suzuki
Yugo Shibagaki
Kiyoki Kitagawa
Kunio Morozumi
Yoshiro Fujita
Makoto Mizutani
Takashi Shigematsu
Kengo Furuichi
Keiji Fujimoto
Naoki Kashihara
Hiroshi Sato
Seiichi Matsuo
Ichiei Narita
Yoshitaka Isaka
Publikationsdatum
19.06.2020
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 10/2020
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-020-01913-9

Weitere Artikel der Ausgabe 10/2020

Clinical and Experimental Nephrology 10/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.